MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$324,052K
Proceeds from issuance of
common stock under atm...
$65,582K
Proceeds from exercise of
options and employee...
$6,856K
Net cash provided by
financing activities
$396,490K
(decrease) increase in
cash, cash...
-$10,534K
Canceled cashflow
$396,490K
Equity-based compensation
expense
$46,277K
Non-cash lease expense
$3,677K
Depreciation expense
$1,418K
Accounts payable
$150K
Maturities of marketable
securities
$467,873K
Net cash used in
operating activities
-$227,450K
Canceled cashflow
$51,522K
Net cash used in
investing activities
-$179,574K
Canceled cashflow
$467,873K
Net loss
-$255,843K
Other assets
$8,467K
Amortization of discounts on
marketable securities
$7,501K
Operating lease liability
-$3,981K
Prepaid expenses and
other current assets
$2,106K
Accrued expenses
-$1,074K
Purchases of marketable
securities
$642,300K
Purchases of property and
equipment
$5,147K
Back
Back
Cash Flow
source: myfinsight.com
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)